Overview of reviewed preclinical studies on LB100. Studies reflect a review of the literature as of May 1, 2022.
Investigators (year) | Tumor type | Treatment method | Outcome |
---|---|---|---|
Cui et al.21 (2020) | Glioblastoma | LB100 and CAR-T cell therapy | Anti-CAIX CAR-T cell therapy and LB100 combination therapy significantly increased tumor-infiltrating lymphocytes (P < 0.05) and prolonged survival (P < 0.001) in xenograft U251-Luc GBM mice. |
Maggio et al.22 (2020) | Glioblastoma | LB100 and PD-1 inhibition | Combination therapy, compared with monotherapy, significantly increased survival of syngeneic GL261-Luc GBM mice (P < 0.05). Complete tumor regression occurred in 25% of combination-treated mice but was not observed in other treatment or control groups. |
Mirzapoiazova et al.23 (2022) | Small-cell lung cancer | LB100, carboplatin, atezolizumab, and PD-L1 inhibition | LB100 and carboplatin combination treatment resulted in significantly smaller tumor size in xenograft SCLC mice than controls (P < 0.001). LB100 administration also increased carboplatin uptake in tumor cells (P < 0.001). Triple therapy with LB100, the PD-1 inhibitor atezolizumab, and anti-PD-L1 starkly destroyed H446 SCLC tumor cell spheroids, increased infiltration by activated T cells, and increased tumor cell death in vitro. |
Uddin et al.24 (2020) | Triple-negative breast cancer | LB100 only | LB100 monotherapy significantly decreased tumor volume in mice bearing MB468 TNBC xenografts. |
Yen et al.25 (2021) | Colorectal cancer, adenocarcinoma, triple-negative breast cancer, and pancreatic cancer | LB100 and PD-1 inhibition | LB100 and anti-PD-1 co-treatment in multiple cancerous syngeneic mouse models resulted in MLH1 protein loss, greater microsatellite instability, and significantly smaller tumor volumes than those in control groups (P = 0.01), corresponding to increased tumor neoantigen expression. |
Zhang et al.26 (2015) | Osteosarcoma | LB100 and cisplatin | Combination therapy, compared with cisplatin or LB100 alone, resulted in significantly smaller tumor volumes in mice bearing 143B OS xenografts (P < 0.05). Pulmonary metastases were observed in only 20% of combination-treated mice, compared with 80% of mice treated with cisplatin alone mice and 100% of mice treated with LB100 alone. |
Liu et al.27 (2018) | Mucoepidermoid carcinoma | LB100 and cisplatin | Co-treatment of MEC cells with LB100 and cisplatin decreased PP2A activity to 84.98% of control levels in vitro. Combination-treated xenograft UM-HMC1 MEC mice also exhibited a significantly smaller tumor volume than did mice treated with either drug alone. |
Song et al.28 (2021) | Esophageal squamous cell carcinoma | LB100 and paclitaxel | LB100 administration attenuated PP2A expression and decreased MCL1 protein levels (P < 0.001) in paclitaxel-resistant ESCC in vitro. In vivo, mouse models of DR150 paclitaxel-resistant ESCC were treated with LB100 monotherapy and showed significant inhibition of tumor growth (P < 0.05). |
Hu et al.29 (2017) | Acute myelogenous leukemia | LB100 and daunorubicin | LB100 monotherapy increased the proportion of patient-derived AML cells in G2/M phase from 13.4% to 31.5% in vitro. LB100 and daunorubicin combination therapy significantly increased cytolysis in these cell lines in vitro (P < 0.01). |
Lai et al.30 (2018) | Chronic myelogenous leukemia | LB100 and dasatinib | Combination therapy resulted in significantly fewer BCR-ABL transcripts in transgenic CML mice than controls (P < 0.01). The combination also yielded a survival benefit over dasatinib monotherapy (P = 0.018) and vehicle (P = 0.001). |
Ho et al.31 (2018) | Meningioma | LB100 and radiation | LB100 and concomitant radiation induced cell death by mitotic catastrophe in vitro. Mice bearing malignant IOMM-LEE meningioma xenografts demonstrated a survival benefit when treated with combination therapy compared with either monotherapy (P < 0.05). |
Hao et al.32 (2018) | Chordoma | LB100 and radiation | Co-treatment increased the proportion of cells arrested in G2/M phase of the cell cycle in vitro. Tumor size was significantly smaller in xenograft U-CH1 chordoma mice treated with combination therapy than in mice in the control (P = 0.028), LB100 alone (P = 0.0014), or radiation alone (P = 0.0273) groups. |